Arteriovenous Plasma Multiomics and Inflammatory Factors in Patients With Disorders of Consciousness
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Patient clinical outcome
研究概览
简要总结
In order to determine the abnormal cerebral metabolism in the pathological state, we compared the blood of internal jugular vein, superior vena cava and radial artery during central venous catheterization. Metabonomics, proteomics and inflammatory factor microarray were used to detect the material differences in arteriovenous blood of patients with disorders of consciousness. At the same time, we concurrently compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.
详细描述
Background:It is unclear what substances the brain needs to ingest for its activity under pathological conditions
Method:The uptake and release of substances by the brain were observed by comparing arterial blood with internal jugular vein blood;The characteristics of brain metabolites were observed by comparing internal jugular vein blood with superior vena cava blood. Compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.
Objective
By analyzing different substances, this paper briefly describes the pathological mechanism of patients with disorders of consciousness, and looks for potential prognostic biomarkers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Patients with consciousness disorder caused by various severe brain injuries
排除标准
- •Patients who have been judged brain dead
- •There are persistent epileptic activity, inhibition or seizure inhibition patterns
- •Recent fever, abnormal liver and kidney function
- •Previous history of neurological or mental illness
- •Have a history of tumor
- •Inflammatory bowel diseases, hyperlipidemia, gastritis
结局指标
主要结局
Patient clinical outcome
时间窗: 12 months
The patients were followed up for 12 months after blood collection to observe the clinical outcome
次要结局
未报告次要终点